Sanofi Scores Two Major China Approvals For Rare Blood Disorder Drugs

Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
newscase

Blueprint Medicines’ Ayvakit Demonstrates Sustained Efficacy in Long-Term Studies

New long-term clinical data for Blueprint Medicines' drug Ayvakit (avapritinib) were presented at the ASH congress in Orlando, reinforcing the treatment's pr ...

Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

Sanofi’s Bleeding-Disorder Treatments Get Approval in China

Two treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China.